Peng Lu Selected Research

6'-sialyllactose

1/2021	The human milk oligosaccharides 2'-fucosyllactose and 6'-sialyllactose protect against the development of necrotizing enterocolitis by inhibiting toll-like receptor 4 signaling.
1/2021	Insights image for "The human milk oligosaccharides 2'-fucosyllactose and 6'-sialyllactose protect against the development of necrotizing enterocolitis by inhibiting toll-like receptor 4 signaling."

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Peng Lu Research Topics

Disease

49	Neoplasms (Cancer) 06/2022 - 01/2005
18	Inflammation (Inflammations) 01/2022 - 01/2012
10	Breast Neoplasms (Breast Cancer) 02/2022 - 01/2012
10	Infections 12/2021 - 12/2007
10	Necrotizing Enterocolitis 09/2021 - 02/2014
7	Hepatocellular Carcinoma (Hepatoma) 11/2021 - 03/2006
5	Tuberculosis (Tuberculoses) 12/2021 - 01/2016
5	Body Weight (Weight, Body) 01/2020 - 06/2015
5	Type 2 Diabetes Mellitus (MODY) 01/2019 - 04/2008
4	Carcinogenesis 03/2022 - 01/2014
4	Neoplasm Metastasis (Metastasis) 09/2020 - 11/2015
4	Lung Injury 03/2019 - 05/2015
4	Urinary Bladder Neoplasms (Bladder Cancer) 11/2015 - 01/2005
4	Colitis 01/2013 - 10/2011
4	Skeletal Abnormalities Mandibular Hypoplasia Auditory Canal Atresia Short Stature 12/2012 - 12/2007
3	Idiopathic Pulmonary Fibrosis 05/2022 - 01/2021
3	Leukemia 01/2022 - 11/2012
3	Colonic Neoplasms (Colon Cancer) 06/2021 - 01/2012
3	Hereditary Angioedemas 01/2021 - 04/2020
3	Weight Loss (Weight Reduction) 01/2021 - 06/2019
3	Brain Injuries (Brain Injury) 01/2021 - 11/2018
3	Obesity 01/2021 - 01/2019
3	B-Cell Lymphoma (Lymphoma, B Cell) 10/2020 - 01/2012
3	Ischemic Stroke 05/2020 - 01/2013
3	Asthma (Bronchial Asthma) 02/2020 - 01/2013
3	Cardiovascular Diseases (Cardiovascular Disease) 01/2020 - 09/2015
3	Carcinoma (Carcinomatosis) 01/2020 - 07/2007
3	Hypoxia (Hypoxemia) 01/2020 - 09/2015
3	Hypertension (High Blood Pressure) 01/2018 - 09/2015
3	Stroke (Strokes) 01/2018 - 01/2013
3	Rheumatoid Arthritis 01/2017 - 01/2014
3	Dengue (Dengue Fever) 01/2012 - 06/2008
2	Rupture 09/2022 - 05/2022
2	Cardiotoxicity 08/2022 - 01/2022
2	Acute Kidney Injury (Acute Renal Failure) 07/2022 - 09/2019
2	Wilms Tumor (Wilm's Tumor) 05/2022 - 01/2022
2	Atrophy 01/2022 - 01/2020
2	Pancreatic Neoplasms (Pancreatic Cancer) 01/2022 - 01/2020
2	Mitochondrial Diseases (Mitochondrial Disease) 01/2022 - 01/2019
2	Fibrosis (Cirrhosis) 01/2022 - 09/2012
2	Ischemia 01/2022 - 01/2017
2	Cognitive Dysfunction 10/2021 - 12/2018
2	Dementia (Dementias) 10/2021 - 01/2021
2	Glaucoma 10/2021 - 01/2019
2	Poisoning 08/2021 - 01/2020
2	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 01/2021 - 01/2019
2	Neuroinflammatory Diseases 01/2021 - 01/2021
2	Wounds and Injuries (Trauma) 10/2020 - 05/2015

Drug/Important Bio-Agent (IBA)

13	Proteins (Proteins, Gene)FDA Link 01/2022 - 03/2006
12	Pharmaceutical PreparationsIBA 01/2022 - 03/2013
10	MicroRNAs (MicroRNA)IBA 01/2022 - 01/2014
8	Biological ProductsIBA 01/2022 - 07/2007
7	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2022 - 02/2014
7	Small Interfering RNA (siRNA)IBA 01/2019 - 07/2007
6	Messenger RNA (mRNA)IBA 01/2022 - 09/2012
6	Toll-Like Receptor 4IBA 01/2021 - 06/2015
5	DNA (Deoxyribonucleic Acid)IBA 06/2022 - 04/2008
5	Peptides (Polypeptides)IBA 01/2019 - 12/2007
5	Biomarkers (Surrogate Marker)IBA 12/2016 - 01/2012
4	Reactive Oxygen Species (Oxygen Radicals)IBA 09/2022 - 01/2012
4	LipidsIBA 01/2021 - 01/2018
4	SolutionsIBA 01/2021 - 12/2007
4	OligosaccharidesIBA 01/2021 - 10/2016
4	Drug CombinationsIBA 02/2016 - 01/2013
3	Air Pollutants (Pollutants, Air)IBA 07/2022 - 11/2019
3	LipopolysaccharidesIBA 07/2022 - 12/2018
3	RNA (Ribonucleic Acid)IBA 01/2022 - 07/2007
3	CholesterolIBA 01/2022 - 01/2018
3	Tuberculin (PPD)IBA 12/2021 - 01/2016
3	Glucose (Dextrose)FDA LinkGeneric 01/2021 - 02/2017
3	2'-fucosyllactoseIBA 01/2021 - 10/2016
3	Long Noncoding RNAIBA 01/2021 - 01/2019
3	Caspase 3 (Caspase-3)IBA 10/2020 - 01/2017
3	Environmental Pollutants (Pollutants, Environmental)IBA 10/2020 - 01/2019
3	Therapeutic UsesIBA 01/2018 - 08/2014
3	tocilizumab (atlizumab)FDA Link 01/2017 - 01/2014
3	Formaldehyde (Formol)FDA Link 12/2016 - 12/2007
3	ElementsIBA 09/2015 - 04/2008
3	hydroxide ionIBA 12/2012 - 12/2007
2	nintedanibIBA 05/2022 - 01/2022
2	pirfenidoneIBA 05/2022 - 01/2022
2	Enzyme Inhibitors (Inhibitors, Enzyme)IBA 01/2022 - 01/2020
2	Untranslated RNA (Noncoding RNA)IBA 01/2022 - 01/2021
2	Circular RNAIBA 01/2022 - 01/2022
2	Sincalide FDA Link 01/2022 - 01/2016
2	Retinaldehyde (Retinal)IBA 01/2022 - 01/2020
2	SugarsIBA 01/2022 - 01/2021
2	Interferon-gamma (Interferon, gamma)IBA 12/2021 - 01/2016
2	MethyltransferasesIBA 01/2021 - 09/2015
2	6'-sialyllactoseIBA 01/2021 - 01/2021
2	Phosphotransferases (Kinase)IBA 01/2021 - 01/2019
2	lanadelumabIBA 01/2021 - 11/2020
2	Agammaglobulinaemia Tyrosine KinaseIBA 01/2021 - 01/2020
2	gambogic acidIBA 09/2020 - 01/2019

Therapy/Procedure

18	Therapeutics 01/2022 - 01/2012
9	Drug Therapy (Chemotherapy) 01/2022 - 01/2005
8	Chinese Traditional Medicine (Traditional Chinese Medicine) 06/2021 - 01/2012
3	Aftercare (After-Treatment) 01/2021 - 01/2005
2	Rejuvenation 10/2021 - 01/2021
2	Immunotherapy 01/2021 - 01/2018